Guédat Philippe, Colland Frédéric
Hybrigenics SA, 3-5 Impasse Reille, 75014 Paris, France.
BMC Biochem. 2007 Nov 22;8 Suppl 1(Suppl 1):S14. doi: 10.1186/1471-2091-8-S1-S14.
Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade(R) (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma establishes this system as a valid target for cancer treatment. We review here new patented proteasome inhibitors and patented small molecule inhibitors targeting more specific UPS components, such as E3 ubiquitin ligases and deubiquitylating enzymes. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).
泛素蛋白酶体系统(UPS)失调与包括癌症和神经退行性疾病在内的多种人类疾病的发病机制有关。蛋白酶体抑制剂万珂(硼替佐米)最近被批准用于治疗多发性骨髓瘤和套细胞淋巴瘤,这确立了该系统作为癌症治疗的一个有效靶点。我们在此综述新获得专利的蛋白酶体抑制剂以及靶向更特定UPS组分(如E3泛素连接酶和去泛素化酶)的小分子抑制剂。出版历史:转载自Current BioData的靶向蛋白质数据库(TPdb;http://www.targetedproteinsdb.com)。